LISA PHARMA
ActiveLISA PHARMA has been active since 2016 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €153k and a net result of €26k. Equity is growing by ~65.3% per year across the filed fiscal years. Its solvency ranks better than 31% of 7694 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.6% (low).
Checked score
Score 2025
60
/ 100
Healthy
The score weighs solvency, liquidity and profitability. Bankruptcy probability contributes 35%. Every signal that weighs is under Signals.
Axes · tick = 2024
Profitability59▼-24
Solvency51▲+2
Growth78=
Track record100
Bankruptcy probability, 12 months
0.6%
Low
0%0.5%1.5%4%10%≥ 25%
Credit up to €9k at 30 days acceptable
Liquidity short (current ratio 0.71 against 0.88 in 2024; short-term debt: 58% of total assets), and 74.3% of the assets are financed with debt.
Credit advice for your own amount and term
Signals
Six signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
lowers risk · Lower-failure-rate sector
In this sector companies fail less often than the Belgian average.
Gazette · bankruptcies per sector, NACE 82
Relative position
BE, all sectors
reference
Sector 82
lower
← fewer bankruptcies
more bankruptcies →
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2025Solvency, return and age of the figures
Solvency
25.7%
Return on assets
4.3%
Age of the figures
9 mo
neutral · Filed after the deadline
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 28-08-2026, 28 days later. For context: 47% of the Belgian market files late and the whole 1-to-90-day band measures 2.0% abnormal legal state against a 1.66% average. We show this as a fact and do not score it.
NBB · 9 filingsDeviation from the deadline
2025
28 d late
2024
48 d late
2023
170 d late
2022
9 d late
2021
18 d late
2020
24 d late
2019
93 d late
← before the deadline
after the deadline →
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven monthsPosition in the running window
17-09-2026 today31-12-2026 close31-07-2027 deadline
Financials · fiscal year 2025, micro schema
Turnover
Not included in this filing
EBIT margin
Not included in this filing
Net result
€26k▼ 61.5%
2024 · €67k
2018: €-31k
2019: €24k
2020: €8k
2021: €9k
2022: €46k
2023: €26k
2024: €67k
2018 → 2025
Working capital
€-102k▼ 303%
2024 · €-25k
2018: €-23k
2019: €-16k
2020: €-7k
2021: €14k
2022: €278
2023: €-43k
2024: €-25k
2018 → 2025
Multi-year overview
Every figure with its change against the year before
▲ rise
▼ fall
Line20212022202320242025Trend
Equity€-11k-€35k€61k▲ 71.7%€128k▲ 110%€153k▲ 20.2%
Operating result€23k-€69k▲ 206%€59k▼ 14.5%€90k▲ 51.8%€39k▼ 56.4%
Net result€9k-€46k▲ 414%€26k▼ 44.4%€67k▲ 162%€26k▼ 61.5%
Result per fiscal year
Operating resultNet result
The operating result falls in 2025; 2025 is 56% below 2024.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €597k
Fixed assets
€352k▼ 0.3%
Current assets
€245k▲ 29.9%
Equity and liabilities €597k
Equity
€153k▲ 20.2%
Debt
€444k▲ 7.1%
The debt ratio falls from 76.4% to 74.3%. Equity and debt are higher.
Key figures and ratios
EBITDA
€57k▼
2024 · €108k
Cash flow
€43k▼
2024 · €85k
Solvency
25.7%▲
2024 · 23.6%
Current ratio
0.71▼
2024 · 0.88
Quick ratio
0.47▼
2024 · 0.50
Debt / equity
2.89▼
2024 · 3.24
ROE
16.8%▼
2024 · 52.4%
ROA
4.3%▼
2024 · 12.3%
Interest coverage
4.19▼
2024 · 5.82
Debt
€444k▲
2024 · €414k
Debt ≤ 1 year
€346k▲
2024 · €214k
Debt > 1 year
€97k▼
2024 · €185k
Staff costs
€51k▼
2024 · €63k
Green means a favourable move, even when the figure itself falls: as with debt or debt / equity.
Filed annual accounts
As filed with the NBB · 2025 against 2024
Balance sheet
Code20242025
Assets
Total assets20/58€542k€597k▲
Fixed assets21/28€353k€352k▼
Tangible fixed assets22/27€352k€351k▼
Land and buildings22€199k€184k▼
Plant, machinery and equipment23€144k€158k▲
Furniture and vehicles24€9k€8k▼
Financial fixed assets28€2k€2k▲
Current assets29/58€188k€245k▲
Stocks and contracts in progress3€81k€81k=
Stocks30/36€81k€81k=
Amounts receivable within one year40/41€80k€136k▲
Trade receivables40€48k€133k▲
Other amounts receivable41€31k€2k▼
Current investments50/53€26k€26k▲
Deferred charges and accrued income490/1€2k€2k=
Equity and liabilities
Total equity and liabilities10/49€542k€597k▲
Equity10/15€128k€153k▲
Contributions10/11€19k€19k=
Reserves13€101k€101k=
Tax-exempt reserves132€101k€101k=
Profit (loss) carried forward14€8k€34k▲
Amounts payable17/49€414k€444k▲
Amounts payable after more than one year17€185k€97k▼
Financial debts170/4€185k€97k▼
Amounts payable within one year42/48€214k€346k▲
Current portion of amounts payable after more than one year42€75k€88k▲
Financial debts43€2k€16k▲
Credit institutions430/8€2k€16k▲
Trade debts44€124k€190k▲
Suppliers440/4€124k€190k▲
Taxes, remuneration and social security45€13k€28k▲
Taxes450/3-€28k
Remuneration and social security454/9€13k€470▼
Other amounts payable47/48-€24k
Accrued charges and deferred income492/3€15k-
Income statement
Code20242025
Remuneration, social security and pensions62€63k€51k▼
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€18k€18k▼
Other operating charges640/8€1k€1k▲
Gross operating margin9900€173k€109k▼
Operating profit (loss)9901€90k€39k▼
Financial income75/76B-€16
Recurring financial income75-€16
Financial charges65/66B€19k€14k▼
Recurring financial charges65€19k€14k▼
Profit (loss) for the period before taxes9903€71k€26k▼
Income taxes67/77€5k-
Profit (loss) for the period9904€67k€26k▼
Profit (loss) for the period to be appropriated9905€67k€26k▼
Appropriation of the result
Profit (loss) to be appropriated9906€8k€34k▲
Profit (loss) brought forward from the previous period14P€-59k€8k▲
The notes to these accounts (10 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
28-08
NBB filing
Annual accounts filed
fiscal year 2025 · micro schema · 28 days late
2025
31-12
Financial
Equity above €150kEq €153k ▲20.2%
7 profitable years in a row build equity to €153k.
17-09
NBB filing
Annual accounts filed
fiscal year 2024 · full schema · 48 days late
17-01
NBB filing
Annual accounts filed
fiscal year 2023 · full schema · 170 days late
2024
31-12
Financial
Highest result since 2018net €67k ▲162%
Operating result €90k, net result €67k, both a record.
31-12
Financial
Equity above €100kEq €128k ▲110%
6 profitable years in a row build equity to €128k.
2023
09-08
NBB filing
Annual accounts filed
fiscal year 2022 · micro schema · 9 days late
2022
18-08
NBB filing
Annual accounts filed
fiscal year 2021 · full schema · 18 days late
2021
24-08
NBB filing
Annual accounts filed
fiscal year 2020 · full schema · 24 days late
2020
01-11
NBB filing
Annual accounts filed
fiscal year 2019 · micro schema · 93 days late
2019
31-12
Financial
Back to profitnet €24k
Net result €24k after one loss-making year.
13-08
NBB filing
Annual accounts filed
fiscal year 2018 · micro schema · 13 days late
2018
31-08
NBB filing
Annual accounts filed
fiscal year 2017 · micro schema · 31 days late
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Directors · office · real estate
Directors
3 acts for this company are in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Ukkel · 1 establishment unit since 2016
Cannot be placed on the map
This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
Zijdeteeltstraat 81180 UkkelGround area
429 m²
Building footprint
250 m²
Volume, LiDAR
3,485 m³
2 parcels, Brussels · tallest building 20.0 m, ±6 floors. Linked by address, not a title deed.
1 establishment unit
LISA PHARMA
since 20162.252.299.913
2 parcels
Brussels
2
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 21616G0070/00W003 | Brussels | 248 m² | 1 · 88 m² | 10.3 m · 3 fl. |
| 21007A0034/00Z004 | Brussels | 181 m² | 1 · 162 m² | 20.0 m · 6 fl. |
Linked by address, not proof of ownership
Methodology
via registered seat: 1 · via establishment units: 1
2 of 2 parcels with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Similar companies · same sector, comparable size
MASSA KATRIEN
BE 0880.850.367
Beveren-Kruibeke-Zwijndrecht · Eq €153k
LIVE & CO
BE 0445.787.551
Orp-Jauche · Eq €153k
JAMA MANAGEMENT
BE 0779.419.150
Liège · Eq €153k
House of Tiles
BE 0474.440.262
Roeselare · Eq €153k
ALBRACO
BE 0665.670.616
Wielsbeke · Eq €153k
Of 24,505 companies in sector 82990 we hold annual accounts for 9,396. 7,114 are within a factor 10 of this equity.See the whole sector
Company data · Crossroads Bank
Identification
Legal formPrivate limited company
Founded30-03-2016
Fiscal year end31-12
Activities, NACEBEL
47730Retail sale of pharmaceutical products
82990Other business support services
Sources
Crossroads Bank for EnterprisesNational Bank · 9 filingsAddress and cadastre registers
Data from official sources, last processed on 16-09-2026. Scores and ratios are computed by Checked and are not a credit decision.